Does Endometriosis Cause Cancer? What Research Actually Shows

The question behind the fear: “Am I going to get cancer from endometriosis?”

If you live with endometriosis (and if you also have or suspect adenomyosis), it’s common to hear scary headlines about a “cancer link.” Many patients end up wondering whether endometriosis causes cancer—or whether every endometrioma (ovarian endometriosis cyst) is a ticking time bomb.

The most accurate, patient-centered answer from current research is this: *endometriosis is associated with a higher risk of certain cancers, but malignant transformation is uncommon, and most people with endometriosis will never develop cancer. Researchers are also getting clearer on why* an association exists—without claiming that endometriosis automatically turns into cancer.

This article synthesizes findings from multiple recent papers (including large cohort study data, imaging studies, and molecular work) to help you understand what the combined evidence does—and does not—mean for your health.

So…does endometriosis cause cancer?

In medicine, “cause” is a very high bar. The evidence more strongly supports that endometriosis can be part of a biological pathway that—rarely—contributes to specific cancers, rather than being a direct cause that leads to cancer for most patients.

Across reviews of the literature, the clearest and most consistent association is between endometriosis and two ovarian cancer subtypes: endometrioid and clear cell ovarian cancers (often discussed as endometriosis-associated ovarian cancers). Importantly, broader claims like “endometriosis causes gynecologic cancers” are not equally supported for every cancer type; for example, cervical cancer is generally not considered to have a true etiologic link in this body of work. But in the case of uterine or endometrial cancer, associative but not causative links have been reported but are nowhere near causative.

How rare is malignant transformation? A 2025 review discussing the endometriosis–cancer connection describes malignant transformation as uncommon, with reported ranges around 0.7–2.5%. That number can vary depending on how a study defines transformation and which population it examines, but the practical message is: risk is not zero, but it’s also not the usual outcome. Keep in mind though, especially when high-risk family history and genetics are present, especially during late forties and beyond, millions of women have endometriosis. Even with a conservative 1% risk of malignancy in a million women with endo, this means 10,000 women are at high risk. So, the risk is relatively tiny but it is prudent to keep this in mind to stay safe.

Why is there any link at all? A patient-friendly explanation

Several lines of research point to a “perfect storm” that can exist in some endometriosis lesions—especially in ovarian endometriomas and deep infiltrating endometriosis (DIE):

1. Chronic inflammation and oxidative stress

Endometriosis lesions can create a chronic inflammatory environment. In general, long standing inflammation from any condition is considered highly associated, if not causative, of cancer. One newer study looking at immune-metabolic patterns found that in endometriosis, the local pelvic fluid environment can be relatively iron-rich with higher oxidative stress (ROS)—and these were linked to each other (more free iron tracked with more ROS). Oxidative stress matters because it can contribute to cellular damage over time.

2. Immune tolerance that allows lesions to persist

That same immune-metabolic research suggests pelvic macrophages (immune cells that can either attack threats or support tissue repair) may skew toward an “M2-like” profile in endometriosis. M2-leaning immune behavior is often described as more “tolerant” or “wound-healing,” which may help explain why endo lesions can persist rather than being cleared. The notion here is that long-standing inflammatory cells can eventually go bad.

3. Genetic “driver” mutations in the epithelium (the gland-like cells)

A focused review of epithelial mutations reports that driver mutations (such as in PIK3CA, KRAS, and ARID1A) have been found not only in endometriosis-associated ovarian cancers, but also in endometriosis epithelium itself—including tissue that still appears benign. Meanwhile, stromal cells (the supporting tissue) may be mutation-free but show changes that promote inflammation and hormone resistance, creating a neighborhood that can push mutated epithelial cells to grow.

Taken together, modern thinking is less “endometriosis is cancer” (even if it can spread and behave aggressively) and more like: some endometriosis lesions may acquire mutations, then live in a chronic inflammatory/oxidative environment that can (rarely) promote malignant transformation—particularly in the ovary.

“But my blood tests are normal—does that mean I’m safe?”

Not necessarily—and also not necessarily concerning. One important theme from immune profiling studies is that endometriosis may be very ‘local’ biologically. In one cohort, standard blood-type inflammatory markers were lower in endometriosis than in advanced ovarian cancer, even though pelvic fluid findings told a different story.

This helps explain a frustrating reality many patients face: you can have severe symptoms and significant disease with normal or nonspecific bloodwork. It also explains why common markers like CA-125, CA19-9 and HE4 can be difficult to interpret. A 2025 review emphasizes that these biomarkers and standard imaging are used clinically, but specificity is limited—meaning abnormal results don’t automatically equal cancer, and normal results don’t always rule out important disease.

If transformation is rare, who should worry the most?

Research points toward risk being concentrated in particular situations, rather than evenly spread across everyone with endometriosis.

A recurring “higher attention” category in the literature is atypical endometriosis (a pathology diagnosis that looks more concerning under the microscope), which some papers discuss as a potential precancerous-type lesion. This form of microscopically "atypical" is not the same as clinically atypical endo lesions that have been described which call out endo implants that don't display a classic brown "powder burn" look. Those surgeon-described atypical implants are more white or vesicular (bubbles) in appearance and do not have pre-cancer implications.

Molecular alterations such as ARID1A changes are also discussed as potential future tools for risk stratification—though this is not yet routine clinical care for most patients. These alterations have been found most often in patients with DIE implants.

There’s also an important genetic counseling nuance: a large multicenter study of nearly 17,000 BRCA1/BRCA2 carriers found self-reported endometriosis was uncommon (2.4%), and ovarian cancer prevalence was not higher among those reporting endometriosis (it was lower in simple comparisons). This does not prove endometriosis is protective in BRCA carriers, because the analysis was descriptive and could be influenced by risk-reducing surgery and other differences—but it does suggest the endometriosis–ovarian cancer relationship may not look the same in every risk group.

Can imaging help tell “benign endometrioma” from “something more”?

This is one of the most practical areas of progress. A 2025 diagnostic imaging study looked at advanced MRI techniques— Intravoxel Incoherent Motion (IVIM) plus T2 mapping—in patients with pathology-confirmed benign endometriosis versus endometriosis-associated ovarian cancer. In that dataset, cancers tended to show lower quantitative MRI values (lower diffusion-related and T2 measures), and a combined model performed better than any single parameter (reported AUC around 0.87, with sensitivity and specificity in the low 80% range).

PET-CT scans are not generally regarded as being accurate in determining if cancer is present in endo. However, they are often used for ovarian cancer. It is still reasonable to consider in some cases because the intensity of the tracer signal can be much higher in cancer compared to endometriosis.

What this means for patients:

• Some centers may be able to extract more risk information from MRI than “it looks complex” versus “it looks simple.”
• But these cutoffs are not universal, and the study was retrospective/single-center—so it’s promising, not definitive.
• Imaging can support triage, but pathology remains the final diagnosis when cancer is a concern.

Where does adenomyosis fit into the cancer conversation?

Many patients have both endometriosis and adenomyosis, and the worry often generalizes to “Does either condition mean cancer risk is elevated?”

The strongest cancer association in this set of references is still focused on endometriosis and specific ovarian cancer subtypes. Adenomyosis research here contributes a different point: adenomyosis may have distinctive molecular features, but that does not automatically translate into increased cancer risk.

For example, a tissue study found higher expression of a protein called Numb (NUMB) in adenomyosis tissues compared with controls, especially in the myometrium (uterine muscle). The authors connect NUMB biology to pathways involved in invasive growth (like Notch signaling), and they also explored cancer datasets where NUMB alterations were associated with different survival patterns in endometrial carcinoma. This is interesting biology, but it does not demonstrate that adenomyosis becomes cancer or that patients need new screening.

A separate large surgical pathology review of hysterectomy cases underscores another key patient reality: coexisting gynecologic conditions are common. Fibroids (leiomyomas) and polyps frequently coexist with endometriosis/adenomyosis, and people with both conditions had especially high fibroid rates in that surgical population. The same study observed more endometrial cancer diagnoses in the adenomyosis-only group, but importantly, adjusted analysis did not support adenomyosis as an independent factor—so it’s a signal to interpret cautiously, not a conclusion that adenomyosis causes cancer.

What symptoms should prompt evaluation (even if you have “known endo”)?

Because endometriosis and adenomyosis can explain a lot of pain and bleeding, new symptoms can get dismissed as “just endo.” The research on limited specificity of markers and imaging reinforces that persistent change matters.

Consider prompt evaluation if you have:

• New or rapidly worsening pelvic pain, especially after a period of stability
• A growing ovarian cyst or an endometrioma that changes in appearance
• Unexplained weight loss, persistent bloating, early satiety, or other ongoing abdominal symptoms
• Abnormal uterine bleeding patterns—especially bleeding after menopause, or heavy bleeding that is changing over time (which may also reflect fibroids/polyps)

None of these automatically mean cancer. They do mean it’s reasonable to ask, “Do we need updated imaging? Do we need tumor markers? Is referral indicated?”

Practical takeaways: how to talk with your clinician

Use your appointment time to clarify risk based on your situation rather than general statistics.

Here are focused questions you can bring:

• “Based on my history and imaging, am I in a higher-risk group (for example, a long-standing endometrioma, atypical features, or concerning growth)?”
• “If I have an ovarian endometrioma, what changes on ultrasound or MRI would make you concerned?”
• “Would an MRI (and does your center use quantitative methods) add useful information in my case?”
• “How should we interpret CA-125, CA19-9 or HE4 for me, given they’re not specific?”
• “Could my symptoms be explained by coexisting issues like fibroids or polyps—and should we check for them?”

What we still don’t know (and why headlines can be scary and mislead)

Even with better molecular tools, major gaps remain:

• Most mutation and pathway studies don’t prove cause-and-effect. Finding mutations or immune patterns in lesions helps build models, but doesn’t tell us who will progress.
• Many datasets are surgical or referral populations, which can overrepresent more severe cases.
• Biomarkers and imaging models need external validation, especially across different MRI scanners and protocols.
• Risk is not uniform. Genetics (like BRCA status), lesion location and depth(ovary vs elsewhere), and pathology features (atypia) likely modify risk—so a single scary number can be misleading.

The bottom line

Endometriosis absolutely does not mean you are “destined” to get cancer. The best overall synthesis of current evidence is that endometriosis is linked to a higher risk of specific ovarian cancer subtypes, but malignant transformation is rare. The most compelling explanations involve a mix of local inflammation/oxidative stress, immune tolerance, and epithelial mutations—especially in ovarian endometriomas and DIE.

If you think you may be at higher risk, or know that you are, or you’re worried, the most productive next step is not panic—it’s personalized risk discussion: what your imaging shows, whether lesions are stable, whether symptoms are changing, and what follow-up makes sense for you.